Evaluation and comparison of short chain fatty acids composition in gut diseases

作     者：Elena Niccolai Simone Baldi Federica Ricci Edda Russo Giulia Nannini Marta Menicatti Giovanni Poli Antonio Taddei Gianluca Bartolucci Antonino Salvatore Calabrò Francesco Claudio Stingo Amedeo Amedei 

作者机构：Department of Experimental and Clinical Medicine University of Florence Florence 50134 Italy Department of Biomedical Experimental and Clinical Sciences “Mario Serio” University of Florence Florence 50134 Italy Department of Neurosciences Psychology Drug Research and Child Health Section of Pharmaceutical and Nutraceutical Sciences University of Florence Florence 50134 Italy Department of Statistics Computer Science Applications “G.Parenti” Florence 50134 Italy Department of Biomedicine Azienda Ospedaliera Universitaria Careggi Florence 50134 Italy 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2019年第25卷第36期

页      面：5543-5558页

核心收录：

学科分类：10[医学] 

基　　金：Supported by Italian Society for Celiac Disease and Foundation for Celicac Disease,No.007_FC_2016 Regione Toscana(The Programma Attuativo Regionale Toscana funded by FAS),No.MICp ROBIMM 

主　　题：Short chain fatty acids Microbiota Colorectal cancer Adenoma Celiac disease 

摘      要：BACKGROUND An altered (dysbiosis) and unhealthy status of the gut microbiota is usually responsible for a reduction of short chain fatty acids (SCFAs) concentration. SCFAs obtained from the carbohydrate fermentation processes are crucial in maintaining gut homeostasis and their determination in stool samples could provide a faster, reliable and cheaper method to highlight the presence of an intestinal dysbiosis and a biomarker for various gut diseases. We hypothesize that different intestinal diseases, such as celiac disease (CD), adenomatous polyposis (AP) and colorectal cancer (CRC) could display a particular fecal SCFAs’ signature. AIM To compare the fecal SCFAs’ profiles of CD, AP, CRC patients and healthy controls, using the same analytical method. METHODS In this cross-sectional study, we defined and compared the SCFAs’ concentration in fecal samples of 9 AP, 16 CD, 19 CRC patients and 16 healthy controls (HC). The SCFAs’ analysis were performed using a gas-chromatography coupled with mass spectrometry method. Data analysis was carried out using Wilcoxon ranksum test to assess pairwise differences of SCFAs’ profiles, partial least squaresdiscriminate analysis (PLS-DA) to determine the status membership based on distinct SCFAs’ profiles, and Dirichlet regression to determine factors influencing concentration levels of SCFAs. RESULTS We have not observed any difference in the SCFAs’ amount and composition between CD and healthy control. On the contrary, the total amount of SCFAs was significantly lower in CRC patients compared to HC (P = 0.044) and CD (P = 0.005). Moreover, the SCFAs’ percentage composition was different in CRC and AP compared to HC. In detail, HC displayed higher percentage of acetic acid (P value = 1.3 × 10-6) and a lower amount of butyric (P value = 0.02192), isobutyric (P value = 7.4 × 10-5), isovaleric (P value = 0.00012) and valeric (P value = 0.00014) acids compared to CRC patients. AP showed a lower abundance of acetic acid (P value = 0.